SI3656869T1 - Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja - Google Patents

Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja

Info

Publication number
SI3656869T1
SI3656869T1 SI201531452T SI201531452T SI3656869T1 SI 3656869 T1 SI3656869 T1 SI 3656869T1 SI 201531452 T SI201531452 T SI 201531452T SI 201531452 T SI201531452 T SI 201531452T SI 3656869 T1 SI3656869 T1 SI 3656869T1
Authority
SI
Slovenia
Prior art keywords
stem cells
engraftment
modulation
agent
combination
Prior art date
Application number
SI201531452T
Other languages
English (en)
Inventor
Judith A. Shizuru
Kipp Andrew Weiskopf
Aaron Michael Ring
Akanksha Chhabra
Peter Schnorr
Irving L. Weissman
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55400510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3656869(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of SI3656869T1 publication Critical patent/SI3656869T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
SI201531452T 2014-08-26 2015-08-26 Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja SI3656869T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462041989P 2014-08-26 2014-08-26
EP19198976.3A EP3656869B1 (en) 2014-08-26 2015-08-26 Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

Publications (1)

Publication Number Publication Date
SI3656869T1 true SI3656869T1 (sl) 2021-03-31

Family

ID=55400510

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531452T SI3656869T1 (sl) 2014-08-26 2015-08-26 Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja

Country Status (14)

Country Link
US (3) US10406179B2 (sl)
EP (4) EP4257145A3 (sl)
CA (2) CA3229961A1 (sl)
CY (1) CY1123730T1 (sl)
DK (2) DK3656869T3 (sl)
ES (3) ES2845898T3 (sl)
FI (1) FI3186395T4 (sl)
HR (1) HRP20210057T1 (sl)
HU (2) HUE052725T2 (sl)
LT (1) LT3656869T (sl)
PL (2) PL3186395T5 (sl)
PT (2) PT3656869T (sl)
SI (1) SI3656869T1 (sl)
WO (1) WO2016033201A1 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2804617B9 (en) * 2012-01-17 2021-04-07 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ES2845898T3 (es) 2014-08-26 2021-07-28 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
WO2016065245A1 (en) * 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
CA2982115A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
MY185014A (en) 2015-08-07 2021-04-30 Alx Oncology Inc Contructs having a sirp-alpha domain or variant thereof
WO2017035480A1 (en) * 2015-08-26 2017-03-02 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
KR20230066647A (ko) * 2016-06-17 2023-05-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110461876B (zh) 2017-01-20 2024-05-17 海德堡医药研究有限责任公司 用于耗尽cd137+细胞的组合物和方法
EP3573629A4 (en) * 2017-01-30 2020-10-14 The Board of Trustees of the Leland Stanford Junior University NON-GENOTOXIC CONDITIONING REGIME FOR STEM CELL TRANSPLANTATION
CA3055957A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
CN111183155B (zh) 2017-08-02 2024-02-20 凡恩世制药(北京)有限公司 抗cd47抗体及其用途
US11912780B2 (en) * 2017-10-25 2024-02-27 Actinium Pharmaceuticals, Inc. Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
WO2019113437A1 (en) * 2017-12-08 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
EP3801635A4 (en) * 2018-06-07 2022-04-06 Magenta Therapeutics, Inc. THERAPEUTIC METHODS USING ANTIBODY-DRUG CONJUGATE (ADC)
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CA3117816A1 (en) 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
WO2020112870A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
US20220211885A1 (en) * 2019-04-25 2022-07-07 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
JP2022533253A (ja) * 2019-05-24 2022-07-21 フォーティ セブン， インコーポレイテッド ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023164744A1 (en) * 2022-03-01 2023-09-07 CSL Innovation Pty Ltd Methods of bone marrow conditioning
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183555A1 (en) * 2022-03-25 2023-09-28 Memorial Sloan-Kettering Cancer Center Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
EP1783139B8 (en) 1996-10-01 2009-09-23 Geron Corporation Human telomerase catalytic subunit
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2004002425A2 (en) * 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
AU2003296958A1 (en) * 2002-12-13 2004-07-09 Genetix Pharmaceuticals, Inc. Therapeutic retroviral vectors for gene therapy
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20100226927A1 (en) * 2006-11-03 2010-09-09 Weissman Irving L Selective immunodepletion of endogenous stem cell niche for engraftment
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
US8758750B2 (en) * 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
PL3789038T3 (pl) 2010-05-14 2023-01-23 The Board Of Trustees Of The Leland Stanford Junior University Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
EP2804617B9 (en) * 2012-01-17 2021-04-07 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
ES2845898T3 (es) 2014-08-26 2021-07-28 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody

Also Published As

Publication number Publication date
DK3656869T3 (da) 2021-01-04
EP3186395A4 (en) 2018-03-21
EP4257145A2 (en) 2023-10-11
DK3186395T3 (da) 2019-11-25
PL3186395T5 (pl) 2023-06-12
EP3822364A1 (en) 2021-05-19
EP3186395A1 (en) 2017-07-05
US20220347224A1 (en) 2022-11-03
US20170224737A1 (en) 2017-08-10
PT3186395T (pt) 2019-11-20
LT3656869T (lt) 2021-01-25
ES2763248T3 (es) 2020-05-27
CA2958884C (en) 2024-02-27
EP3656869A1 (en) 2020-05-27
EP4257145A3 (en) 2023-10-18
CY1123730T1 (el) 2022-05-27
HRP20210057T1 (hr) 2021-03-05
HUE052725T2 (hu) 2021-05-28
ES2845898T3 (es) 2021-07-28
US10406179B2 (en) 2019-09-10
EP3186395B2 (en) 2023-03-29
CA2958884A1 (en) 2016-03-03
PT3656869T (pt) 2021-01-13
US11419897B2 (en) 2022-08-23
FI3186395T4 (fi) 2023-05-25
ES2945588T3 (es) 2023-07-04
WO2016033201A1 (en) 2016-03-03
CA3229961A1 (en) 2016-03-03
US20200129557A1 (en) 2020-04-30
EP3186395B1 (en) 2019-09-25
EP3656869A8 (en) 2020-06-10
ES2763248T5 (es) 2023-06-22
EP3822364B1 (en) 2023-05-10
PL3656869T3 (pl) 2021-05-17
PL3186395T3 (pl) 2020-02-28
HUE046387T2 (hu) 2020-03-30
EP3656869B1 (en) 2020-11-11
DK3186395T4 (da) 2023-05-08

Similar Documents

Publication Publication Date Title
PL3656869T3 (pl) Wszczepienie komórek macierzystych z kombinacją środka, który celuje w komórki macierzyste i modulowanie sygnałowania immunoregulatorowego
IL281264B (en) Complete activity modulation
ZA201604795B (en) Catheter devices with valves and related methods
GB201418282D0 (en) Storage device and assembly
PL3066017T3 (pl) Zamknięcie metalowe z zaczepami do mocowania pod niskim naciskiem
HK1213974A1 (zh) 儲藏箱以及冰箱
ZA201700495B (en) Signaling of modulation configuration
SG11201702475VA (en) Methods and compositions for modulating th-gm cell function
ZA201605289B (en) Mushroom line b12998-s39 and methods and uses therefor
IL252191B (en) Compositions and methods for modulating at2r activity
GB2531826B (en) Devices and methods for pulse-width modulation
GB2528698B (en) Location-specific messaging
GB201415002D0 (en) Cell modulation